Bausch + Lomb Corporation (BLCO)
NYSE:BLCO
Want to see BLCO full AI Analyst Report?
Top Page
Bausch + Lomb Corporation
(NYSE:BLCO)
Select Model
Select Model
Rating:55Neutral
Price Target:
$15.50
▼(-7.85% Downside)
Action:ReiteratedDate:04/30/26
The score is anchored by improving fundamentals but still-limited quality of earnings: revenue and operating profitability are trending better and leverage has improved, yet net losses and thin free-cash-flow conversion remain key constraints. The latest earnings call was a clear positive with raised guidance and strong margin expansion, but technicals are weak (below key moving averages with negative MACD) and valuation lacks support given losses and no dividend.
Positive Factors
Consistent Revenue Growth
Multi-year revenue expansion to $5.2B TTM shows durable top-line momentum across contact lenses, pharma and surgical franchises. This scale supports distribution leverage, recurring consumables revenue, and underpins continued investment in R&D and commercialization over the next several quarters.
Negative Factors
Persistent Net Losses
Despite operating gains, continued net losses and negative returns limit retained earnings and the quality of reported profits. This structural earnings shortfall constrains capacity to convert improved EBIT into sustainable net income and weakens long‑term investor return prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Multi-year revenue expansion to $5.2B TTM shows durable top-line momentum across contact lenses, pharma and surgical franchises. This scale supports distribution leverage, recurring consumables revenue, and underpins continued investment in R&D and commercialization over the next several quarters.
Read all positive factors
Bausch + Lomb Corporation (BLCO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.67B
Dividend YieldN/A
Average Volume (3M)405.48K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue Growth7.85%
EPS Growth39.85%
CountryUS
Employees13,500
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.08
Shares Outstanding354,318,200
10 Day Avg. Volume391,487
30 Day Avg. Volume405,477
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)0.94
Price to Sales (P/S)1.18
P/FCF Ratio-91.56
Enterprise Value/Market Cap1.84
Enterprise Value/Revenue2.00
Enterprise Value/Gross Profit2.91
Enterprise Value/Ebitda14.64
Forecast
1Y Price Target
$18.60Price Target Upside10.58% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)0.8
Revenue Forecast (FY)$5.46B
Bausch + Lomb Corporation Business Overview & Revenue Model
Company Description
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact le...
How the Company Makes Money
BLCO primarily makes money by selling eye health products through a mix of consumer retail channels and professional/clinical channels. A major revenue stream comes from vision care products, including contact lenses (sold via eye care professiona...
Bausch + Lomb Corporation Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how much revenue each business segment generates, highlighting core strengths and areas of growth or decline within the company’s operations.
Shows how much revenue each business segment generates, highlighting core strengths and areas of growth or decline within the company’s operations.
Data provided by:
The Fly
The FlyBausch + Lomb Corporation Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call emphasized substantial progress on execution: consistent revenue growth, large adjusted EBITDA and margin expansion, strong Pharma and premium product momentum, active pipeline and elevated R&D investment — all supported by a modest guidance raise. Lowlights were mostly transitional or seasonal (Surgical field-force rebuild, weather-related disruptions, regional softness, prescription seasonality, and cash/capex timing). Overall, the positives—material margin improvement, strong product-level growth (notably Miebo, Xiidra, Daily SiHy, premium IOLs), and upgraded guidance—outweigh the temporary challenges.Positive Updates
Top-Line Growth
Total company revenue of $1.244 billion in Q1, up 6% year-over-year on a constant currency basis; FX provided a tailwind of approximately $42 million in the quarter.
Negative Updates
Surgical Segment Near-Term Disruption
Surgical revenue only increased 1% ($228 million) and missed expectations due to weather-related procedure disruptions, reimbursement pressure in select markets, and a deliberate U.S. surgical field force rebuild that created near-term transition impacts.
Read all updates
Q1-2026 Updates
Positive
Negative
Top-Line Growth
Total company revenue of $1.244 billion in Q1, up 6% year-over-year on a constant currency basis; FX provided a tailwind of approximately $42 million in the quarter.
Read all positive updates
Company Guidance
Management raised full‑year revenue guidance by $45 million to $5.42–5.52 billion (implying ~5.3%–7.2% constant‑currency growth, ~+30 bps vs. prior) and increased adjusted EBITDA guidance by $10 million to $1.01–1.06 billion (≈19% margin at the midpoint, ~16% YoY EBITDA growth and roughly 3x revenue growth), while forecasting a ~$50 million full‑year currency tailwind, adjusted gross margin of ~62%, R&D at 7.5%–8% of revenue, interest expense of about $365 million, an adjusted tax rate of ~19% and unchanged full‑year CapEx of ~$285 million (weighted to H1); Q1 that informed the raise included $1.244 billion revenue (+6% YoY; ~$42M FX tailwind), $200 million adjusted EBITDA (+59% YoY) and 16.1% EBITDA margin (+500 bps), 61.2% adjusted gross margin (+170 bps), adjusted R&D of $101 million (+15–17% YoY), adjusted operating cash flow of $45 million and CapEx of $100 million, and management reiterated a target to reach ~3.5x net leverage by year‑end 2028.Bausch + Lomb Corporation Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
66
Positive
Cash Flow
44
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.20B | 5.10B | 4.79B | 4.15B | 3.77B | 3.77B |
| Gross Profit | 3.58B | 3.00B | 2.92B | 2.50B | 2.25B | 2.30B |
| EBITDA | 712.00M | 572.00M | 601.00M | 499.00M | 598.00M | 733.00M |
| Net Income | -219.00M | -360.00M | -317.00M | -260.00M | 6.00M | 182.00M |
Balance Sheet | ||||||
| Total Assets | 13.78B | 14.02B | 13.47B | 13.44B | 11.14B | 10.82B |
| Cash, Cash Equivalents and Short-Term Investments | 268.00M | 383.00M | 305.00M | 334.00M | 380.00M | 174.00M |
| Total Debt | 39.00M | 5.37B | 4.94B | 4.68B | 2.55B | 140.00M |
| Total Liabilities | 7.33B | 7.50B | 6.92B | 6.52B | 4.04B | 1.42B |
| Stockholders Equity | 6.38B | 6.45B | 6.47B | 6.85B | 7.03B | 9.33B |
Cash Flow | ||||||
| Free Cash Flow | 4.33M | -66.00M | -59.00M | -198.00M | 170.00M | 680.00M |
| Operating Cash Flow | 340.39M | 283.00M | 232.00M | -17.00M | 345.00M | 873.00M |
| Investing Cash Flow | -466.16M | -455.00M | -412.00M | -2.11B | -215.00M | -214.00M |
| Financing Cash Flow | 172.25M | 225.00M | 178.00M | 2.08B | 81.00M | -712.00M |
Bausch + Lomb Corporation Technical Analysis
Positive
16.82
Price Trends
16.89
Negative
16.87
Negative
15.80
Positive
Market Momentum
<0.01
Negative
54.05
Neutral
76.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLCO, the sentiment is Positive. The current price of 16.82 is above the 20-day moving average (MA) of 16.21, below the 50-day MA of 16.89, and above the 200-day MA of 15.80, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.05 is Neutral, neither overbought nor oversold. The STOCH value of 76.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLCO.
Bausch + Lomb Corporation Risk Analysis
Bausch + Lomb Corporation disclosed 53 risk factors in its most recent earnings report. Bausch + Lomb Corporation reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bausch + Lomb Corporation Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $4.07B | 40.58 | 8.52% | ― | 11.84% | 5.03% | |
64 Neutral | $12.27B | 30.60 | 4.83% | ― | 5.69% | -2.65% | |
63 Neutral | $4.64B | 24.79 | 9.72% | 0.29% | 12.70% | 24.60% | |
60 Neutral | $6.67B | 188.46 | 2.37% | ― | 16.36% | ― | |
55 Neutral | $5.67B | -16.79 | -3.41% | ― | 7.85% | 39.85% | |
52 Neutral | $2.35B | -3.81 | -35.24% | 5.61% | -2.98% | 34.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
BLCO
Bausch + Lomb Corporation
15.90
4.40
38.26%
COO
Cooper Co
62.90
-19.40
-23.57%
XRAY
DENTSPLY SIRONA
11.75
-1.81
-13.36%
MMSI
Merit Medical Systems
68.18
-27.48
-28.73%
RGEN
Repligen
118.31
-23.20
-16.39%
STVN
Stevanato Group
17.00
-4.32
-20.27%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.